| [1] |
Dent R,Trudeau M,Pritchard KI,et al. Triple negative breast cancer: Clinical features and patterns of recurrence[J]. Clin Cancer Res,2007,13 (15):4429-4434.
|
| [2] |
Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the socalled triple-negative phenotype: a population-based study from the California Cancer Registry[J]. Cancer, 2007,109(9):1721-1728.
|
| [3] |
Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes[J]. Clin Cancer Res,2007,13 (8):2329-2334.
|
| [4] |
Haffty BG,Yang Q,Reiss M,et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer[J]. J Clin Oncol,2006,24 (36):5652-5657.
|
| [5] |
Clarke M, Coates AS, Darby SC,et al. Adjuvant chemotherapy in oestrogenreceptor-poor breast cancer: patient-level metaanalysis of randomised trials [J]. Lancet,2008,371 (9606):29-40.
|
| [6] |
Berry DA, Cirrincione C, Henderson IC, et al. Estrogenreceptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer [J]. JAMA,2006,295 (14):1658-1667.
|
| [7] |
Chen J, Jiang P, Wang HJ,et al. The efficacy of molecular subtyping in predicting postoperative recurrence in breastconserving therapy: a 15-study meta-analysis [J]. World J Surg Oncol,2014,12:212.
|
| [8] |
Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathological primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy [J]. J Clin Oncol,1999,17 (2):460-469.
|
| [9] |
Kaufmann M, Hortobagyi GN, Goldhirsch A, et al.Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update [J]. J Clin Oncol, 2006, 24(12):1940-1949.
|
| [10] |
Kuroi K, Toi M, Tsuda H, et al. Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer [J]. Biomed Pharmacother, 2005,59(2):S387-S392.
|
| [11] |
von Minckwitz G, Untch M, Blohmer JU,et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes [J]. J Clin Oncol,2012,30 (15):1796-1804.
|
| [12] |
Rouzier R, Perou CM, Symmans WF,et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy [J]. Clin Cancer Res, 2005, 11 (16):5678-5685.
|
| [13] |
Carey LA, Dees C, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes [J]. Clin Cancer Res,2007,13 (8):2329-2334.
|
| [14] |
Liedtke C,Mazouni C,Hess KR,et al. Response to neoadjuvant therapy and long term survival in patients with triple-negative breast cancer [J]. J Clin Oncol,2008,26 (8):1275-1281.
|
| [15] |
Huober J, von Minckwitz G, Denkert C, et al. Effect of neoadjuvant anthracyclinetaxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study[J]. Breast Cancer Res Treat,2010,124 (1):133-140.
|
| [16] |
Boughey JC, McCall LM, Ballman KV,et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 ( Alliance)prospective multicenter clinical trial[J]. Ann Surg,2014,260(4):608-616.
|
| [17] |
Gülben K, Berberoˇglu U, Kina V, et al. Breast cancer subtypes can be a predictor of pathologic complete response and survival in the neoadjuvant setting for T4 noninflammatory breast cancer[J]. Acta Chir Belg,2014,114(3):153-159.
|
| [18] |
Yin Y, Zhang P, Xu BH, et al. Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer[J]. J Huazhong Univ Sci Technolog Med Sci,2013,33(2):262-265.
|
| [19] |
Martin M,Romero A,Cheang MC,et al. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer[J]. Breast Cancer Res Treat,2011,128 (1):127-136.
|
| [20] |
Chen DR, Lu DY, Lin HY, et al. Mesenchymal stem cellinduced doxorubicin resistance in triple negative breast cancer[J]. Biomed Res Int,2014,2014:532161.
|
| [21] |
Chang HR, Glaspy J, Allison MA,et al. Differential response of triple-negative breast cancer to a docetaxel and carboplatin based neoadjuvant treatment[J]. Cancer, 2010,116(18):4227-4237.
|
| [22] |
Ma WY, Zhang P, Zhang BL,et al. Phase Ⅱclinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer[J]. Zhonghua Zhong Liu Za Zhi,2012,34(10):770-774.
|
| [23] |
Roy V, Pockaj BA, Allred JB,et al. A Phase Ⅱtrial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage Ⅱor Ⅲbreast cancer: NCCTG study N0338[J]. Am J Clin Oncol,2013,36(6):540-544.
|
| [24] |
Kern P, Kalisch A, Kolberg HC, et al. Neoadjuvant,anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response[J]. Chemotherapy,2013,59(5):387-394.
|
| [25] |
Sharma P, Stecklein SR, Kimler BF, et al. Efficacy of neoadjuvant carboplatin/docetaxel chemotherapy in sporadic and BRCA-associated triple-negative breast cancer (TNBC)[EB/OL]. [2015-01-20]. http:/ /meetinglibrary. asco. org/content/136919-151.
|
| [26] |
Zhukova L, Okruzhnova M.Preliminary results of a prospective pilot study of cisplatin(C) and doxorubicin(D) as neoadjuvant chemotherapy (NACT) for locally advanced triple-negative breast cancer (TNBC) [EB/OL]. [2015-01-20]. http:/ /meetinglibrary.asco.org/content/ 134068-144.
|
| [27] |
Sikov WM, Berry DA, Perou CM,et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-perweek paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱto Ⅲtriple-negative breast cancer: CALGB 40603(Alliance) [J].J Clin Oncol,2015,3(1):13-21.
|
| [28] |
Von Minckwitz G, Schneeweiss A, Loibl S,et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial[J]. Lancet Oncol,2014,15(7):747-756.
|
| [29] |
Babyshkina N, Malinovskaya E, Patalyak S,et al. Neoadjuvant chemotherapy for different molecular breast cancer subtypes:a retrospective study in Russian population[J]. Med Oncol,2014,31(9):165.
|
| [30] |
Abraham J1, Robidoux A, Tan AR et al. Phase Ⅱrandomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel ( WP) or eribulin ( E) followed by doxorubicin and cyclophosphamide (AC) in women with locally advanced HER2-negative breast cancer(LABC):NSABP FB-9[J]. Breast Cancer Res Treat,2015,152(2):399-405.
|
| [31] |
Futsuhara K, Inoue K, Shigenori E,et al. Feasibility study of TS-1 additional therapy for the triple-negative breast cancer received neoadjuvant or adjuvant chemotherapy (SBCCSG14)[EB/OL]. [2015-01-20]. http:/ /meetinglibrary. asco. org/content/99256? media=vm& oster=1.
|
| [32] |
Gerber B, Loibl S, Eidtmann H, et al. Neoadjuvant bevacizumab and anthracycline-taxane- based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study ( GBG 44) [ J]. Ann Oncol, 2013,24(12):2978-2984.
|
| [33] |
von Minckwitz G, Loibl S, Untch M,et al. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto) [J]. Ann Oncol,25(12):2363-2372.
|
| [34] |
von Minckwitz G, Müller BM, Loibl S,et al. Cytoplasmic poly( ADP-ribose ) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy[J]. J Clin Oncol, 2011,29(16):2150-2157.
|
| [35] |
Llombart A, Lluch A, Villanueva C,et al. SOLTI NeoPARP:A phase Ⅱ, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC) [EB/OL].[2015-01-20 ]. http:/ /meetinglibrary. asco. org/ ontent/95054-114.
|
| [36] |
Dent RA, Lindeman GJ, Clemons M,et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triplenegative breast cancer[J]. Breast Cancer Res,2013,15(5):R88.
|
| [37] |
Nabholtz JM,Abrial C,Mouret-Reynier MA,et al. Multicentric neoadjuvant phase Ⅱstudy of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triplenegative breast cancer: identification of biologically defined signatures predicting treatment impact[J]. Ann Oncol, 2014,25(8):1570-1577.
|
| [38] |
Penault-llorca F,Abrial C,Dauplat MM,et al. Response to the anti-EGFR antibody panitumumab combined with standard neoadjuvant chemotherapy in triple negative breast cancer(TNBC):the immune and IGFR pathways[EB/OL]. [2015-01-20]. http:/ /www. researchgate. net/publication/275450806_Abstract_4669_Response_to_the_anti-EGFR_antibody_panitumumab _ combined _ with _ standard _ neoadjuvant _chemotherapy_in_triple_negative_breast_cancer_%28TNBC%29_the_immune_and_IGFR_pathways.
|
| [39] |
Therasse P, Mauriac L, Welnicka-Jaskiewicz M,et al. Final results of a randomized phase Ⅲ trial comparing cyclophosphamide, epirubicin, and fluorouracil with a doseintensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study[J]. J Clin Oncol,2003,21(5):843-850.
|
| [40] |
Gluz O, Nitz UA, Harbeck N,et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial[J].Ann Oncol,2008,19(5):861-870.
|
| [41] |
Giacchetti S, Porcher R, Lehmann-Che J,et al. Long-term survival of advanced triple- negative breast cancers with a doseintense cyclophosphamide/anthracycline neoadjuvant regimen[J]. Br J Cancer,2014,110(6):1413-1419.
|
| [42] |
Moebus V, Jackisch C, Lueck HJ, et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer:mature results of an AGO phase Ⅲstudy[J]. J Clin Oncol,2010,28(17):2874-2880.
|
| [43] |
Frasci G, D'Aiuto G, Comella P, et al. Weekly cisplatin,epirubicin, and paclitaxel with granulocyte colony-stimulating factor support versus triweekly epirubicin and paclitaxel in locally advanced breast cancer:Final analysis of a SICOG phaseⅢstudy[J]. Br J Cancer,2006,95:1005-1012.
|
| [44] |
Sánchez-Muñoz A, Plata-Fernández Y, Fernández M,et al.Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients[J]. Clin Transl Oncol,2014,16(6):548-554.
|